Skip to main content
. 2015 Apr 12;6(15):13703–13717. doi: 10.18632/oncotarget.3800

Figure 5. Resveratrol increases sorafenib induced cell growth inhibition in both sorafenib-resistant HCC cells and nude mice bearing liver orthotopic tumor.

Figure 5

(A, B) HCC-LM3 and Bel-7402 cells were exposed to resveratrol (20 and 40 μM, respectively), sorafenib (5 μM), and combination treatment for 24 h, and cell proliferation was analyzed using the CCK-8 assay. Columns represent the mean ± s.e.m. of three independent experiments (*P < 0.05; **P < 0.01). (C–G) In a subcutaneous xenograft mouse model, mice were treated with resveratrol (10 mg/kg BW per day) alone, sorafenib (10 mg/kg BW per day) alone, or combination treatment for 30 days. At the time points indicated, the following measurements were performed: diameters of tumors (C, D), changes in body weight (E), and the percent of TUNEL-positive tumor cells (F and G). Points or columns represent mean values, whereas bars represent s.d. (*P < 0.05; **P < 0.01).